Progyny has delivered four consecutive earnings beats averaging 15.5% above estimates with excellent free cash flow conversion of 296%, but the stock has reached analyst targets and the current price offers no meaningful upside cushion.
Thesis pillars
- Quality Cashflow Strength→Stable
- Earnings Beat Consistency↑Improving
- Valuation Target Exhaustion↓Deteriorating
- +1 more pillar — see the Why tab for full reasoning
Pillars as of Jul 3, 2026, based on the 10-K filed Feb 27, 2026
Progyny, Inc. (PGNY) Stock Analysis
Breakout setup
Healthcare · Healthcare Plans
Hold if already holding. Not a fresh buy at $27.87, but acceptable to hold if already in. Reasons: Thin upside margin: 7.4%; Earnings in 6 days (event risk).
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle;... Read more
Hold if already holding. Not a fresh buy at $27.87, but acceptable to hold if already in. Reasons: Thin upside margin: 7.4%; Earnings in 6 days (event risk). Chart setup: Golden cross, above all MAs, RSI 50, MACD bullish. Maintain position. Not compelling to add more. Score 5.9/10, moderate confidence.
Passes 5/8 gates (positive momentum, clean insider activity, no SEC red flags, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio and earnings proximity 6d<=7d. Suitability: aggressive.
Recent developments
updated 2026-10-29Recent Developments — Progyny, Inc.
Latest news
- NEWS Progyny Inc (PGNY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey — TradingKey neutral
- NEWS Progyny Inc (PGNY) Earnings Forecast: Future EPS & Revenue Growth Estimates - tradingkey.com — tradingkey.com neutral
- NEWS Progyny Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs — Revelio Labs neutral
- NEWS Should Value Investors Buy Progyny (PGNY) Stock? - Yahoo Finance — Yahoo Finance positive
- NEWS Progyny Buyback Raises Questions On Capital Returns And Growth Plans - simplywall.st — simplywall.st positive
Generated 2026-10-29T11:14:35Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMCustomertechnology industry clients10-K Item 1A: 'In addition, we generate a significant portion of our revenue from clients in the technology industry.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
10 dimensions · all in-band
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $27.87, but acceptable to hold if already in. Reasons: Thin upside margin: 7.4%; Earnings in 6 days (event risk). Chart setup: Golden cross, above all MAs, RSI 50, MACD bullish. Maintain position. Not compelling to add more. Analyst target $29.94 (+7.4%), stop $26.15 (−6.6%), A.R:R 0.7:1. Score 5.9/10, moderate confidence.
Analyst target: $29.94 (+7.4% upside). Analyst target $29.94 (+7.4%), stop $26.15 (−6.6%), A.R:R 0.7:1. Stop-loss: $26.15.
Thin upside margin: 7.4%; Earnings in 6 days (event risk).
Progyny, Inc. trades at a P/E of 30.3 (forward 12.0). TrendMatrix value score: 7.2/10. Verdict: Hold.
18 analysts cover PGNY with a consensus score of 4.2/5. Average price target: $34.
What does Progyny, Inc. do?Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits...
Progyny, Inc., a benefits management company, provides fertility, family building, and women's health benefits solutions in the United States. It offers fertility benefits solutions, such as differentiated benefits plan design that includes smart cycle treatment bundle; personalized concierge-style member support services; and a selective network of fertility specialists. The company also offers Progyny Rx, an integrated pharmacy benefits solution that provides access to the medications needed during their treatment and offers care management services, as well as pregnancy and postpartum, menopause and midlife, benefit and leave navigation, and parent and child wellbeing solutions. In addition, it provides assistance service program where various services can be offered through a reimbursement program, including adoption, surrogacy, doula, and travel reimbursement when travel is required to receive medical services. The company was formerly known as Auxogyn, Inc. and changed its name to Progyny, Inc. in 2015. Progyny, Inc. was incorporated in 2008 and is headquartered in New York, New York.